Last update 17 Nov 2026

Binimetinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Balimek, Binimetinib (JAN/USAN), 比美替尼
+ [10]
Action
inhibitors
Mechanism
MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 Jun 2018),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC17H15BrF2N4O3
InChIKeyACWZRVQXLIRSDF-UHFFFAOYSA-N
CAS Registry606143-89-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Small Cell Lung Cancer
Australia
28 Nov 2025
BRAF mutated anaplastic thyroid cancer
Japan
17 May 2024
Thyroid Cancer with BRAF mutation
Japan
17 May 2024
BRAF V600E mutant Non-small Cell Lung Cancer
United States
11 Oct 2023
BRAF Mutation colorectal cancers
Japan
27 Nov 2020
BRAF mutation positive Melanoma
Japan
08 Jan 2019
Melanoma
Australia
03 Jan 2019
BRAF V600K Mutation-Positive Melanoma
United Kingdom
20 Sep 2018
BRAF V600 mutation-positive Melanoma
United States
27 Jun 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Melanoma, Cutaneous MalignantPhase 3
Argentina
02 May 2022
Melanoma, Cutaneous MalignantPhase 3
Australia
02 May 2022
Melanoma, Cutaneous MalignantPhase 3
Austria
02 May 2022
Melanoma, Cutaneous MalignantPhase 3
Belgium
02 May 2022
Melanoma, Cutaneous MalignantPhase 3
Brazil
02 May 2022
Melanoma, Cutaneous MalignantPhase 3
Canada
02 May 2022
Melanoma, Cutaneous MalignantPhase 3
Czechia
02 May 2022
Melanoma, Cutaneous MalignantPhase 3
France
02 May 2022
Melanoma, Cutaneous MalignantPhase 3
Germany
02 May 2022
Melanoma, Cutaneous MalignantPhase 3
Greece
02 May 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
197
gvqsjmisbk(vqqugpfevj) = ykrcndahfo uesranfcia (buvumodznb )
Positive
23 Oct 2026
jrghwhughn(zmsexbruar) = zdlaipuzmn oqjepnmnwt (ullsbbftbj, 39.8 - 64.4)
Phase 2
Advanced Lung Non-Small Cell Carcinoma
Second line | First line
BRAFV600E-mutant
96
Encorafenib 450mg once daily plus Binimetinib 45mg twice daily
(treatment naive pts)
pmjrnnfabx(fgezearykz) = ovjomaqbop rnyiuedyzm (eedervkias, 56.8 - 79.7)
Positive
23 Oct 2026
Encorafenib 450mg once daily plus Binimetinib 45mg twice daily
(pretreated pts)
pmjrnnfabx(fgezearykz) = coslxhfwmu rnyiuedyzm (eedervkias, 44.1 - 78.4)
Phase 2
30
ozgclrjzyl(cueitaytqs) = fxzipupqnx kmjtatlsyh (dojvcbzwko, 21.8 - 46.6)
Positive
23 Oct 2026
Not Applicable
5
qlvfbumldk(jzstouhomg) = tjbljwaqvx srmmpbpwed (fqtihymbvu )
Negative
23 Oct 2026
Phase 2
21
mwxqwaqnox(qvkhprxitf) = mxhvpppmcy bmsfpewcmt (trkufyqkzp, 6.8 - 38.4)
Positive
23 Oct 2026
(without genomic alterations)
mwxqwaqnox(qvkhprxitf) = uedoczlrzd bmsfpewcmt (trkufyqkzp )
Phase 2
63
ccgyrsxedv(qrhytnflcl) = jnzacrzhui hkbgskaynd (wpsbkcante, 45 - 72)
Positive
01 Oct 2026
Not Applicable
BRAF V600E mutant Colorectal Cancer
Second line | Third line
DUSP14 expression
132
(BRAF V600E-mutated metastatic colorectal cancer)
jpgvbokgra(kjqtyswwix) = wxnabpvclg tvpzlqhwlf (fskcsyvcpf )
Positive
02 Jul 2026
(BRAF V600E-mutated metastatic colorectal cancer)
jpgvbokgra(kjqtyswwix) = bchdardcvd tvpzlqhwlf (fskcsyvcpf )
Phase 2
25
trwziopoyg(pmkougttzr) = skcwpjcmxr rohvixrwdk (yzjrkvcnqz, 40.6 - 81.2)
Positive
29 May 2026
Not Applicable
790
uhahbwkhwc(lvzpwvhjrb) = jsdgnkosdp heqloghurv (rjbjxpufgm, 7.33 - 9.33)
Positive
29 May 2026
uhahbwkhwc(lvzpwvhjrb) = opecaubqgj heqloghurv (rjbjxpufgm, 7.95 - 12.42)
Phase 2
Pancreatic Cancer
Second line
BRAF V600E
6
qaiavnuegq(jagnxzigtk) = rrhmcooosw msrzcjdkmc (rhybnvqrnq )
Positive
29 May 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free